Fourteen-year patency of an anterior tibial artery-saphenous vein fistula in an ambulatory patient.

Creative Commons License

Pulathan Z., Altun G.

Case Reports in vascular Medicine, vol.4135532, no.1155, pp.1-4, 2022 (Peer-Reviewed Journal)

  • Publication Type: Article / Case Report
  • Volume: 4135532 Issue: 1155
  • Publication Date: 2022
  • Doi Number: 10.1155/2022/4135532
  • Journal Name: Case Reports in vascular Medicine
  • Journal Indexes: MEDLINE
  • Page Numbers: pp.1-4
  • Karadeniz Technical University Affiliated: Yes


Background. Ankle arteriovenous fistulas are the rarest vascular access type among lower extremity fistulas for hemodialysis

patients with end-stage renal disease. Here, we present a case of a tibial-saphenousfistula that remained open for a long time

despite a recurrent anastomotic aneurysm. Case Presentation. A 43-year-old female patient who had been undergoing

hemodialysis via a right femoral tunnel catheter for six months was referred for recurrent catheter infection and a 4 cm

pulsatile mass in the anterior aspect of the ankle. While she had been undergoing hemodialysis through a right tibial-saphenous fistula for fourteen years, hemodialysis continued after the fistula’s closure due to total occlusion of the great

saphenous vein through the tunneled catheter. After balloon angioplasty to the right subclavian vein, we performed right upper

extremity basilic vein transposition. Later, after starting adequate dialysis from the basilic vein fistula and removing the

femoral catheter, we performed a resection of the anastomotic aneurysm in the right ankle and repaired the anterior tibial

artery. Because this is the only ambulatory patient and the one with the longest patency of ankle arteriovenous fistulas in the

literature and the only case in which the anterior tibial artery was used, the case is presented and discussed in light of the

literature. Conclusion. Despite many complications and low patency rates reported in the literature, ankle vessels should be

considered for autogenous vascular access in selected patients.